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The visualization of Golgi glycosylation defects in patients’ cells
with Congenital Disorders of Glycosylation (CDG) is challenging
and necessitates the use of cumbersome glycan analysis methods
that are barely adapted to clinical research. We show here that
metabolic labelling of patient cells with alkyne-tagged sialic-acid
(SiaNAl) enables an easy and reliable readout assay for the detec-
tion of CDG occurrence. It also provides valuable clues regarding
the pathological processes by assessing the distribution of sialic
acid analogues within the cells.
The Congenital Disorders of Glycosylation (CDG) are a group of
rare human genetic disorders characterized by defects in
glycoconjugates that dramatically illustrate the fundamental
involvement of glycosylation in the intricate design of life.
In the past decade, about 60 diﬀerent types of CDG have been
defined genetically and most of the time, the defects impair the
biosynthesis, addition (CDG-I) and/or remodelling of N-glycans
(CDG-II).1 CDG-I disorders are characterized by reduced occupa-
tion of glycosylation sites on their newly synthesized glycoproteins
while CDG-II disorders lead to the formation of abnormal
glycan structures.2–4 Different methods, based on HPLC and
mass spectrometry (MS), have been applied and developed in
the field of CDG to identify and quantify N/O-glycosylation
deficiencies.5,6 While being extremely powerful, the sensitivity
is often related to the amount of glycoproteins in a sample. Our
goal was to develop an easy method applicable to non-specialized
glycobiology laboratories to evaluate the Golgi glycosylation
efficiency in mammalian living cells. To achieve this objective,
we have evaluated the use of metabolic incorporation of
unnatural monosaccharides into CDG fibroblasts, adapting
the ligand-accelerated CuAAC using BTTAA and the alkyne-
tagged sialic acid (SiaNAl).7,8 Although azido chemical reporter
groups have been developed with success over a wide range of
organisms,9,10 the SiaNal strategy has never been used in a human
pathological context. Noteworthily, the use of azido-analogues to
typify lysosomal disorders in Nemann–Pick disease was described
in a recent report.11
In this context, we have synthesized alkyne-tagged sialic acid
(SiaNAl) (Fig. 1) to metabolically incorporate into glycoconjugates
and visualized it by the use of azido-functionalized fluorophores.
This strategy was applied to cells from healthy individuals, CDG-I
and CDG-II patient cells, and led us to identify and quantify
the glycosylation defects in the diﬀerent CDG patient cells.
Fibroblasts from healthy individuals were metabolically labelled
for periods ranging from 6 to 48 h to allow the incorporation
of the alkyne-tagged sialic acid into newly synthesized glyco-
conjugates. After fixation, cells were permeabilized and labelled
with an azido-545 fluorescent probe to visualize the pool of
labelled sialylated glycoconjugates. As shown in Fig. S1 (ESI†)
we observed distinctive staining patterns suggesting diﬀerential
subcellular localization of labelled sialylated glycoconjugates.
The alkyne-tagged sialic acid, irrespective of the incubation
time, was clearly detected in unpunctuated regions as well as
associated with vesicular structures localized throughout the
cytoplasm (Fig. S1, ESI†). After 24 h of labelling, the alkyne-
tagged sialic acid, presumably bound to glycoproteins and
glycolipids, was additionally observed at the cell surface, likely
due to the targeting of labelled glycoproteins to the plasma
membrane. To further delineate the subcellular localization
of the diﬀerent pools of labelled sialylated glycoconjugates,
Fig. 1 Chemical structures of (left) 5-N-acetyl-b-neuraminic acid (Neu5Ac) and
(right) N-5-pentynoyl-b-neuraminic acid (SiaNAl).
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we performed immunofluorescence staining using organelle-
specific antibodies. TGN46 is a specific marker from the TGN
compartment whereas EEA1 predominantly resides within early
endosomes. As shown in Fig. 2, two pools of labelled sialylated
glycoconjugates can be diﬀerentiated, one perfectly localized
in the Golgi compartment and another one localized in early
endosomes. Staining using diﬀerent fixing methods further
suggested that sialic acid analogues are linked to glycoconjugates
in the identified compartments (Fig. S2, ESI†).
We then compared the incorporation eﬃciency on a com-
prehensive panel of fibroblasts isolated from known CDG-I
and II patients with fibroblasts from a healthy individual.
Known defects included deficiencies in glycosyltransferases or
monosaccharide processing enzymes (PMM2 and ALG11),
Golgi transport proteins (COG7, COG5), Golgi transporters
(ATP6V0A2, TMEM165), and an uncharacterized CDG-II patient
presenting severe Golgi glycosylation deficiencies. Overall,
a sharp decrease, depending on the molecular defects, of the
fluorescence intensity associated to the pool of labelled glyco-
conjugates co-localizing with TGN46 was observed compared to
control cells (Fig. 3 and Fig. S3, ESI†).
Almost no fluorescence associated to alkyne-tagged bound
sialic acid in the perinuclear Golgi region could be detected in
CDG patients with COG7 defect, ATP6V0A2 defect and in the
uncharacterized CDG-IIx patient (observed a decrease of 98%,
93% and 74%, respectively, compared to control). In contrast,
only a slight decrease was seen in milder forms of CDG patients
with defects in TMEM165, MAN1B1 and COG5 (11%, 34% and
44%, respectively, compared to controls). Besides these defects,
it was possible that abnormal incorporation of alkyne-tagged
sialic acid could be caused by a sub-optimal occupation of
glycosylation sites in glycoproteins, as seen in the CDG-I
patients with defects in PMM2 and ALG11. Both types also
presented an intermediate reduction level in the incorporation
of sialic acid into glycoconjugates (56% and 66%, respectively,
compared to control). The observed decreases are directly
proportional to the severity of the known defects but not to
the type of CDG. Nonetheless, it is noteworthy that type II CDG
defects exhibited lower fluorescence intensity on average
than type I.
Aware that the fluorescent quantification could be mis-
represented due to the immunofluorescent protocol, we quanti-
fied the SiaNAl content of all carbohydrate-containing fractions
from two CDG patients presenting very diﬀerent patterns of
alkyne-tagged sialic acid incorporation (PMM2 and COG7) and
control fibroblasts. We purified glycoprotein-, glycolipid- and
cytosolic free sialic acid-containing fractions from each cell type
and quantified their contents in natural (Neu5Ac and Neu5Gc)
and tagged (SiaNAl) sialic acids by reverse phase fluorescence
HPLC.12 In control fibroblasts cultured with medium that was
not supplemented with SiaNAl, all three fractions contained
about 95% of Neu5Ac and 5% of Neu5Gc (data not shown).
Although only present as traces in human cells, significant
quantities of Neu5Gc can be identified when grown in culture
medium supplemented by BSA, likely due to the intake of bovine
Neu5Gc that competes with endogenous Neu5Ac.13 When sup-
plemented with SiaNAl, control fibroblasts contained 86 to 91%
Neu5Ac, 4 to 6% Neu5Gc and 3 to 7% SiaNAl (data not shown).
As shown in Fig. 4a, the total amount of SiaNAl incorporated
into CDG deficient cells was very similar to the one observed in
control cells, establishing that the diﬀerences in incorporation
into glycoconjugates observed by microscopy were not the
result of the modification of sialic acid uptake but of intra-
cellular traﬃcking and/or sialic acid utilization. Strikingly, and
in accordance with the observed loss of Golgi fluorescence by
microscopy, the incorporation of SiaNAl into glycoproteins
dropped by 33% in PMM2 deficient CDG cells and by 66% in
COG7 deficient CDG cells (Fig. 4b). Reciprocally, exogenous free
SiaNAl strongly accumulated into the soluble cytosolic fraction
of COG7 deficient CDG cells. Interestingly, no diﬀerences in
the quantification of SiaNAl incorporated into glycolipids were
observed.
Fig. 2 Fibroblasts from healthy individuals were metabolically labelled with
500 mM of SiaNAl and stained with azido fluorescent probes (sialic acid into
glycoconjugates in red) or antibodies against a late Golgi marker (TGN46 in blue)
and an early endosomal marker (EEA1 in green).
Fig. 3 Diﬀerential incorporation of tagged sialic acid into CDG deficient patients
(see all panels in Fig. S2, ESI†). (a) Fibroblasts from healthy individuals and COG-7
deficient patients were metabolically labeled as in Fig. 2. (b) The associated
fluorescence to the alkyne tagged sialic acid was quantified. For each cell line,
100 cells were quantified and the results are an average of two independent
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For this study, we took advantage of a large collection of
characterized CDG-I and CDG-II cell lines to establish that
alkyne-tagged modified sialic acid can be used to easily assess
the glycosylation defects in cultured cells from patients. Indeed,
all CDG-II deficient cells were shown to express drastically lower
quantities of newly synthesized glycoproteins than control cells.
Defects in the Golgi retrograde traﬃcking as well as in Golgi pH
and Ca2+ homeostasis lead to Golgi glycosylation abnormalities
that involve all types of glycosylate substrates.14,15 Convincingly,
our findings confirmed the severity of sialylation deficiency
observed by mass spectrometry serum profiling in a much
simpler and reliable way. It is particularly true for type II CDGs
such as COG7 deficiencies for which the N-glycome analysis is
not related to the severity of the defect.16 Subcellular quanti-
fication of sialic acids by HPLC further established that this
phenomenon may be the result of diﬀerent processes. For
PMM2 deficient CDG cells, the reduction of overall sialylation
may originate from the combined eﬀects of a reduced uptake of
sialic acid from the medium and a reduced incorporation into
glycoproteins. At the opposite, COG7 deficient patient cells did
not exhibit any reduction in the sialic acid uptake but an
incapacity to transfer it into their glycoproteins, leading to
the accumulation of large quantities of unbound sialic acid
in the cytoplasm.
We used hydroxyl-free sialic acid analogues rather than per-
acetylated ones in order to minimize non-specific crossing of
internal membranes that may result in abnormal localization of
sialic acids. In accordance with the reported data we showed
that exogenous alkyne-tagged sialic acid (SiaNAl) could be
eﬃciently incorporated into cells via newly synthesized Golgi
glycoproteins.17 In our assay, two pools of alkyne-tagged sialic
acids were clearly observed: one in TGN46 positive structures
likely bound to Golgi glycoproteins and one in EEA1 positive
early endosomal structures. The subcellular localization of this
pool suggests a plasma membrane recycling of SiaNAl tagged
glycoproteins. Although the entry mechanisms of alkyne tagged
sialic acid are not entirely solved, one could imagine that sialic
acids enter into the cell by endocytosis.13 This tool could be
used to follow the eﬃcacy of the endocytic pathway which
deficiencies may also lead to Golgi defects.
To conclude, we propose a novel chemical method based on
the estimation of the Golgi glycosylation eﬃciency in patient
cells with suspected glycosylation defects. This strategy may not
only lead to the identification or confirmation of patients with
glycosylation defects but is also of interest to exclude CDG-II
patients presenting an abnormal transferrin isoelectrofocalisa-
tion (TIEF) profile due to secondary causes of hyposialylation as
for patients with severe liver pathology and hemolytic uremic
syndrome. We anticipate that this method will facilitate further
biochemical and cellular experiments in the near future and
speed up the diagnosis of patients with glycosylation defects.
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Fig. 4 Quantification by HPLC of the alkyne tagged sialic acid incorporation into
glycoconjgates in deficient CDG patient cells versus control cells (FC). (a) Quanti-
fication of SiaNAl from total cells and (b) quantification of SiaNAl according
to origin: free SiaNAl, bound to glycosphyngolipid fraction (GSL) or glycoprotein
fraction (GP).Values are averaged from three experiments. The error bars represent
the SEM.
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